HCPLive Network

New Meningitis B Vaccine Strongly Immunogenic

Tuesday, May 8 (HealthDay News) -- Peter C. Richmond, M.B.B.S., from the Princess Margaret Hospital for Children in Subiaco, Australia, and colleagues randomly assigned 511 healthy adolescents to placebo or one of three doses of a vaccine against Neisseria meningitidis serogroup B (recombinant lipoprotein 2086) at zero, two, and six months.

As determined by serum bactericidal assays using human complement (hSBA) against eight strains, the researchers found that seroconversion occurred in 67.9 to 100 percent of subjects at the two highest doses. The immune response was strong, with many having titers up to 16. The vaccine was generally well tolerated, with mild-to-moderate pain at the injection site being the most common local reaction. Systemic events were generally mild to moderate and included fatigue and headache. There was one serious vaccine-related adverse event, which resolved without sequelae, after the third dose of the highest dose.

"The bivalent recombinant lipoprotein 2086 vaccine is immunogenic and induces robust hSBA activity against diverse invasive meningococcus serogroup B disease strains, and the vaccine is well tolerated," Richmond and colleagues conclude. "Recombinant lipoprotein 2086 vaccine is a promising candidate for broad protection against invasive meningococcus serogroup B disease."

Several authors disclosed financial ties to pharmaceutical companies, including Wyeth and Pfizer, both of which funded the study.

Abstract
Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)

A new meningococcus serogroup B vaccine is strongly immunogenic against multiple strains and well tolerated in healthy adolescents, according to a study published online May 7 in The Lancet Infectious Diseases.

Copyright © 2012 HealthDay. All rights reserved.
Further Reading
A defined process is necessary to help physicians hire the right staff for their practice, according to an article published July 24 in Medical Economics.
A defined process is necessary to help physicians hire the right staff for their practice, according to an article published July 24 in Medical Economics.
When it was approved by the FDA in March 2014, apremilast became the first oral medication approved for the treatment of psoriatic arthritis (PsA). Data from clinical trials showed it to be an effective option for patients, with a safer side effect profile than currently used PsA treatments.
As more pediatric surgical procedures being conducted as same-day procedures, parents are assuming responsibility for their children’s immediate post-operative pain management.
Between developing its own pipeline of therapies for patients with hepatitis C and acquiring another company known for its work in this field, it looks like Merck is taking steps to be a larger player in HCV market.
While neonatal vitamin K refusal is rare, parents who refuse vitamin K are less likely to immunize their child, according to a study published online Aug. 18 in Pediatrics.
There is a significantly increased risk of cardiac death associated with clarithromycin use, according to a study published online Aug. 19 in BMJ.
More Reading